Point72 Asset Management, L.P. 13D and 13G filings for Syndax Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-08-18 4:53 pm Purchase | 2025-08-15 | 13G | Syndax Pharmaceuticals, Inc. SNDX | Point72 Asset Management, L.P. | 4,327,952 5.000% | 2,020,128 (+87.53%) | Filing |
| 2025-08-14 5:39 pm Sale | 2025-06-30 | 13G | Syndax Pharmaceuticals, Inc. SNDX | Point72 Asset Management, L.P. | 2,307,824 2.700% | -1,970,023 (-46.05%) | Filing |
| 2025-01-22 5:50 pm Purchase | 2025-01-21 | 13G | Syndax Pharmaceuticals, Inc. SNDX | Point72 Asset Management, L.P. | 4,277,847 5.000% | 1,443,348 (+50.92%) | Filing |
| 2024-02-14 07:01 am Sale | 2023-12-31 | 13G | Syndax Pharmaceuticals, Inc. SNDX | Point72 Asset Management, L.P. | 2,834,499 3.300% | -685,903 (-19.48%) | Filing |
| 2023-10-31 4:26 pm Purchase | 2023-10-30 | 13G | Syndax Pharmaceuticals, Inc. SNDX | Point72 Asset Management, L.P. | 3,520,402 5.100% | 3,520,402 (New Position) | Filing |